top cx logo
cx logo
Explorearrow down
search icon
arrow down

Positive signs for Nantes lab's Covid-19 treatment

The antibody treatment aims to stop patients with Covid-19 becoming seriously ill. Its producers say clinical trials could have started much earlier but the government prioritised vaccine development over treatments

Vials of the Xav-19 treatment. Nantes laboratory proves its medical treatment for Covid is effective

Vials of the Xav-19 treatment. Results from the first stage of clinical trials have been published Pic: @FranceNews24 / FranceNews24 / Twitter

A medical laboratory in Nantes has now completed the first human trials of its promising Covid-19 treatment on 398 patients in 35 French hospitals. 

This means it has completed stage two of the clinical trials, and initial (as yet unofficial) findings show the treatment to be safe and not to have serious side effects. Final results including on its effectiveness in the patients will be published by this summer.

The treatment, called Xav-19, is made up of a cocktail of antibodies that attack the virus in multiple ways.

Preclinical trials previously found that with a sufficient concentration, the treatment neutralised 100% of the virus in a test tube.

In a press release earlier this year the laboratory, Xenothera, said the treatment has the effect of “reducing the risk of worsening in patients with moderate forms of the [Covid-19] disease. XAV-19 works by neutralizing the virus, reducing inflammation and limiting the risk of a cytokine storm [a reaction in the immune system which can cause multisystem organ failure].”

The treatment was also found to have a “blocking effect” on all the main variants including those from the UK, South Africa, and Brazil, the laboratory said.

Trials could have begun earlier

Laboratory president Dr Odile Duvaux said the results showing the treatment works had been “great news” but she was disappointed the clinical trials had not begun earlier.

The clinical trials began in September 2020 but the laboratory had been working on its coronavirus treatment long before the start of the health crisis in 2020. 

In December 2020, Dr Duvaux told The Connexion: “[France] could have been the first in the world to have an antibody treatment against SARS-CoV- 2. In March 2020, we were ready: we had prepared a treatment for previous coronavirus outbreaks and our technology had been tested on patients.”

Read more: ‘Our Covid-19 treatment was ready but red tape stopped us’

She said testing was delayed because the government had prioritised developing vaccines over treatments in the fight to control the epidemic.

The laboratory plans to publish results from the second stage of clinical trials this summer, and hopes the treatment will be given temporary authorisation by medicines safety agency the l'Agence nationale de sécurité du medicament – the first step towards rolling the medicine out for wider use.

It also hopes to sign pre-orders in France and other European countries in order to start industrial production of the treatment.

Related stories

Will Johnson & Johnson Covid vaccine now be used in France?

French start-up makes exoskeletons to support staff in physical roles

French company launches €100m project to create artificial skin

Resident or second-home owner in France?
Benefit from our daily digest of headlines and how-to's to help you make the most of life in France
By joining the newsletter, you agree to our Terms & Conditions and Privacy Policy
See more popular articles
The Connexion Help Guides
featured helpguide
Healthcare in France*
Featured Help Guide
- Understand the French healthcare system, how you access it and how you are reimbursed - Useful if you are new to the French healthcare system or want a more in-depth understanding - Reader question and answer section Aimed at non-French nationals living here, the guide gives an overview of what you are (and are not) covered for. There is also information for second-home owners and regular visitors.
Get news, views and information from France
You have 2 free subscriber articles left
Subscribe now to read unlimited articles and exclusive content
Already a subscriber? Log in now